Primary regulatory
FDA warning about counterfeit Ozempic in the U.S. drug supply chain
FDA alert documenting counterfeit Ozempic in the U.S. drug supply chain.
U.S. Food and Drug AdministrationAccessed 2026-07-12
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-counterfeit-ozempic-alert
Source usage
Not yet linked from a public content page
This record may be retained for an upcoming review or for internal source normalization.
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.